Thiopurines therapy in Inflammatory Bowel Disease: Role of a spectrum of metabolites and enzymes in predicting the response

Shailesh0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients with a definite diagnosis of Ulcerative Colitis (UC) or Crohnâ??s Disease (CD) being initiated on azathioprine/6-mercaptopurine/ 6Tioguanine therapy (designated as thiopurine (TP) therapy) as per standard accepted criteria will be included.

•1. Patients with CD or UC on biologicals, or immunosuppressives other than thiopurines
•2. Subjects who have undergone total procto-coloctomy for UC
•3. Evidence of colorectal dysplasia or malignancies
•4. Patients in whom bowel surgery appears to be imminent
•5. Congenital or acquired immunodeficiency, especially known HIV infections, or evidence
•of other immuno-compromised states
•6. Patients ineligible in any way for TP therapy e. g. known intolerance to the drug
•7. Patients not providing written informed consent for inclusion
•8. Planning to conceive in 17weeks after initiation of therapy

发起方